Explainable AI improves prediction of lymph node metastasis in thyroid cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 24-Oct-2026 10:15 ET (24-Oct-2026 14:15 GMT/UTC)
Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off. Because decreased function of TET enzymes is a common driver of certain forms of blood cancer, researchers tested the effects of vitamin C supplements in patients at risk of developing such malignancies. Results of the investigators’ phase 2 clinical trial are published by Wiley online in CANCER.
Vitamin C is an essential nutrient that supports immune function, promotes wound healing and protects cells from molecular damage. Because many people with pre-cancer blood disorders and blood cancer have chronically low levels of vitamin C, scientists have long aimed to understand if restoring those levels to normal could improve patient outcomes. Now, findings from the randomized, double-blinded, placebo-controlled phase 2 EVITA clinical trial, led by the Van Andel Institute–Stand Up To Cancer® Epigenetics Dream Team, suggest that vitamin C may benefit people with pre-cancerous blood disorders and early-stage blood cancers.
The search for more selective, effective and targeted cancer therapies continues to drive innovation across medicinal chemistry and pharmaceutical research. Heterocyclic Chemistry in Oncology: Promising Agents and Novel Approaches, edited by Smriti Dewangan, Anchal Verma and Varsha Rawat, explores the important role of heterocyclic compounds in modern anticancer drug discovery and development.
Researchers from the Keck School of Medicine of USC are developing a new “plug-and-play” platform that could greatly simplify and speed up the creation of new radiotracers, compounds used in positron emission tomography (PET) scans to visualize diseases such as cancer inside the body and track their progression. The project, supported by a four-year, $2.6 million grant from the National Institute of Biomedical Imaging and Bioengineering, part of the National Institutes of Health, aims to expand the uses of PET imaging, potentially improving patient care while making the technology more affordable and accessible. Scientists can identify promising new biological markers faster than ever, but turning those discoveries into PET tracers remains a challenge. Attaching a radioactive substance to these molecules is a time-consuming and technically demanding process that requires specialized equipment and facilities. To address this bottleneck, the research team is creating a platform that can be used to make a wide range of radiotracers. The platform combines a universal radioactive building block—which can be attached to different biological molecules—with a compact device, about the size of a coffee cup, that rapidly combines the two components to produce new radiotracers. The platform brings together two advanced chemistry approaches: click chemistry and droplet radiochemistry. Click chemistry, a Nobel Prize-winning technique, allows scientists to quickly join molecules together, like buckling a seatbelt. Droplet radiochemistry carries out chemical reactions in extremely small droplets, using tiny amounts of material. Preliminary research suggests the approach can produce new radiotracers that could help detect and study several different types of cancer. One tracer is designed to target fibroblast activation protein, which is found at high levels in many tumors. The team is also testing tracers designed specifically to detect liver and prostate cancer.
Researchers have uncovered a previously unknown gene causing resistance to a leading blood cancer drug and several genes that accelerate lymphoma growth, using a powerful new CRISPR activation library.